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Genetic susceptibility to multiple sclerosis (MS) is associated with the human leukocyte antigen (HLA) DRB1*1501 allele. Here
we show a clear association between DRB1*1501 carrier status and four domains of disease severity in an investigation
of genotype–phenotype associations in 505 robust, clinically well characterized MS patients evaluated cross-sectionally: (i) a
reduction in the N-acetyl-aspartate (NAA) concentration within normal appearing white matter (NAWM) via 1HMR spectroscopy
(P= 0.025), (ii) an increase in the volume of white matter (WM) lesions utilizing conventional anatomical MRI techniques
(1,127mm3; P = 0.031), (iii) a reduction in normalized brain parenchymal volume (nBPV) (P = 0.023), and (iv) impairments in
cognitive function as measured by the Paced Auditory Serial Addition Test (PASAT-3) performance (Mean Z Score: DRB1*1501+:
0.110 versus DRB1*1501-: 0.048; P = 0.004). In addition, DRB1*1501+ patients had signiﬁcantly more women (74% versus
63%; P=0.009) and a younger mean age at disease onset (32.4 years versus 34.3 years; P = 0.025). Our ﬁndings suggest that
DRB1*1501 increases disease severity in MS by facilitating the development of more T2-foci, thereby increasing the potential
for irreversible axonal compromise and subsequent neuronal degeneration, as suggested by the reduction of NAA concentrations
in NAWM, ultimately leading to a decline in brain volume. These structural aberrations may explain the signiﬁcant differences
in cognitive performance observed between DRB1*1501 groups. The overall goal of a deep phenotypic approach to MS is
to develop an array of meaningful biomarkers to monitor the course of the disease, predict future disease behaviour, determine
when treatment is necessary, and perhaps to more effectively recommend an available therapeutic intervention.
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Introduction
The human leukocyte antigen (HLA) DRB11501-DQB1-0602
haplotype is a well-established risk factor for multiple sclerosis
(MS) (Bertrams and Kuwert, 1972; Govaerts et al., 1985;
Barcellos et al., 2003; Oksenberg et al., 2004; Haﬂer et al.,
2007). Fine mapping data suggests that the DRB1 gene itself is
responsible for a signiﬁcant portion of this risk (Ebers et al., 1996;
Oksenberg et al., 2004). In Northern European populations, more
than half of individuals with MS are DRB11501 positive, and
even higher frequencies are observed in some familial MS cohorts
(Haines et al., 1998; Rubio et al., 2002; Barcellos et al., 2006).
Although DRB11501 is the best studied susceptibility allele
in MS, the inﬂuence of the HLA region is complex (Haines
et al., 1998; Barcellos et al., 2002; Sawcer et al., 2005; Yeo
et al., 2007), and other DRB1 variants can also contribute to
MS risk, including DRB104 in Sardinians and Sicilians, and
DRB11503 and DRB103 in African-Americans (Marrosu et al.,
2002; Oksenberg et al., 2004; Brassat et al., 2005). DRB11501
also inﬂuences MS susceptibility in a dose-dependent fashion;
homozygotes are at a several fold higher risk compared with
heterozygotes (Barcellos et al., 2003). Although DRB1 alleles
clearly inﬂuence MS susceptibility, little is known about whether
HLA variation inﬂuences clinical manifestations or outcomes in
MS (Kantarci et al., 2002; Villoslada et al., 2002).
The current study was stimulated by our previous analysis of
the Optic Neuritis Treatment Trial (ONTT) group, in which we
reported that individuals carrying the DRB11501 allele exhibited
higher numbers of focal brain lesions at the time of initial presen-
tation with optic neuritis (Hauser et al., 2000). This observation
suggested that DRB1 genes might inﬂuence the radiological
characteristics of MS patients at an early time point in their disease
course. In the present study, we utilized a large, clinically well-
characterized group of MS patients to further explore the relation-
ship between neuroimaging parameters and DRB11501 carrier
status. In addition to conventional anatomic MR end-points, we
utilized an advanced proton spectroscopic metabolic imaging
metric as a marker of neuronal integrity in regions of normal
appearing white matter (NAWM), which have been reported
to be signiﬁcantly abnormal in MS compared to normal con-
trols (Fu et al., 1998; Oh et al., 2004; Srinivasan et al., 2005),
along with a fully automated, validated technique utilized in the
assessment of normalized brain volume (Smith et al., 2001, 2007).
The results of this analysis led us to test the hypothesis that there
may be a clinical correlation with regard to cognitive performance
and the radiological differences observed between patients who
carry DRB11501 versus those that do not. Thus, we also report
an association between the HLA-DRB11501 gene and cognitive
function.
Methods
Research participants
The population was ascertained through a prospective study of phe-
notype–genotype-biomarker associations in a large cohort of MS
patients followed longitudinally. Patients (aged 18–65 years) evaluated
at the Multiple Sclerosis Center at the University of California, San
Francisco (UCSF) between July 2004 and September 2005 were
invited to participate. Patients with a recent onset of MS were pre-
ferentially recruited, although individuals with all clinical subtypes
of the disease participated. These disease types included: clinically
isolated syndrome (CIS), relapsing remitting MS (RRMS), secondary
progressive MS (SPMS), primary progressive MS (PPMS), and progres-
sive relapsing MS (PRMS). Patients were not entered if they had
experienced a clinical relapse or received treatment with glucocorticos-
teroids within the previous month. The concomitant use of disease
modifying therapies for MS was permitted. The protocol was approved
by the Committee on Human Research at UCSF, and informed consent
was obtained from all participants.
HLA-DRB11501 typing
HLA-DRB1 genotypes were determined using a validated allele-speciﬁc
TaqMan probe-based, 50 nuclease assay speciﬁc for DRB11501. High
quality genomic DNA for all samples, including positive and negative
controls, were organized, and 2 ml were aliquoted into 384 well plates
for PCR ampliﬁcation. An internal positive control (b-globin) was
included in each well to conﬁrm successful ampliﬁcation of the reac-
tion. PCR was carried out in a total volume of 10ml, containing 20 ng
DNA, 1TaqMan Universal PCR Master Mix (Applied Biosystems,
Foster City, California), 0.6 mM DRB11501 speciﬁc primers, 0.3 mM
control primers, 0.225mM VIC-labeled DRB11501 probe, and
0.025 mM 6FAM-labeled control probe. Ampliﬁcation was carried out
in an ABI PRISM 7900HT Sequence Detection System (Applied
Biosystems) with an initial 95C cycle for 10min, followed by
50 cycles of 95C for 15 s and 62C for 1min. Samples were consid-
ered to contain at least one copy of the DRB11501 allele if the
respective cycle exceeded a pre-established threshold.
Image acquisition
Brain MRI scans were performed on all subjects upon entry into the
study, and analyses were carried out without knowledge of disease
subtype, duration or treatment history. MRI images were acquired
using an 8-channel phased array coil in reception and a body coil in
transmission on a 3T GE Excite scanner (GE Healthcare Technologies,
Waukesha, WI). Each MR imaging examination included scout locali-
zers and axial dual-echo spin echo sequences (TE at 20 and 90ms,
TR=2000ms, 51251244 matrix, 240 240132mm3 FOV,
slice thickness = 3mm, interleaved). A high-resolution inversion recov-
ery spoiled gradient-echo T1-weighted isotropic, volumetric sequence
(3D IRSPGR, 11 1mm3, 180 slices) was also performed (TE/TR/
TI = 2/7/400ms, ﬂip angle = 15, 256256180 matrix, 240240
180mm3 FOV, NEX=1). Conventional spin echo, T1-weighted
images were acquired 5min following administration of a single dose
(0.1mM/kg) of contrast agent (TE/TR=8/467ms, 25625644
matrix, 240240132 FOV, NEX=1).
Brain lesions were identiﬁed by medical doctors (M.D.) specializing
in MS (DTO, AB) on simultaneously viewed high-resolution T1-
weighted, T2-weighted, and proton density-weighted images.
Regions of interest (ROI) were drawn based on a semi-automated
threshold with manual editing utilizing in-house software, and T1-
lesion masks created; the process described elsewhere (Blum et al.,
2002). Both intra and inter-observer variability analyses were per-
formed to ensure the accuracy of data acquired. T2-lesion volumes
from ROI selections were calculated by multiplying the area of the
lesion by the slice thickness and the number of slices penetrated
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using in-house software. A qualitative analysis for the presence
of gadolinium enhancement was performed on post-contrast
T1-weighted images.
Brain tissue segmentation and
normalization
Brain segmentation and normalization was performed using SIENAX
(Image Analysis Group, Oxford, UK), a fully automated technique.
T1-lesion masks (described above) were presented to the SIENAX pro-
gramme to correct for misclassiﬁcations of parenchymal tissue while
T1-weighted images were segmented into images representing the
volume of each voxel containing grey matter (GM), WM, cerebral
spinal ﬂuid (CSF), and WM lesion. The lesion masks overrode all
SIENAX tissue classiﬁcations. Normalized tissue volumes were calcu-
lated by summing the lesion corrected, partial volume estimate maps,
multiplied by the brain scalling factor calculated by the SIENAX
programme yielding the normalized brain parenchymal volume (nBPV).
Spectral acquisition and quantiﬁcation
TE-Averaged MRSI spectra were acquired with an in-plane resolution
of 1.21.0 cm over a single slice of thickness 1.5 cm in the supra-
tentorial brain just above the corpus callosum (Srinivasan et al., 2006).
The spectroscopic data were acquired on a 3T GE Excite scanner (GE
Healthcare Technologies, Waukesha, WI) using an 8-channel phased
coil immediately following the acquisition of the anatomical images
and prior to the administration of the contrast agent. The resulting
coil combination data were TE-averaged and the metabolic concentra-
tion of N-acetyl-aspartate (NAA) were obtained using an LCmodel
quantiﬁcation algorithm and corrected for T1 and T2 relaxation
times using similar methods described elsewhere (Ratiney et al.,
2007). Only metabolite estimates within 5% Cramer-Rao error esti-
mates were included in the analysis.
Parameter estimates in ‘Pure’ grey and
white matter
Non-brain regions were removed from the anatomical images using a
semi-automated brain extraction tool. T1-weighted images were seg-
mented into GM, WM, and CSF compartments using a hidden Markov
random ﬁeld model with expectation maximization (Zhang et al.,
2001). The GM and WM maps were re-grid to the spectroscopic
resolution and convolved with the point spread function for spectro-
scopic imaging to yield the percent GM and WM content within each
spectroscopic voxel. By modelling the NAA concentrations and MR
relaxation parameters as a linear function of WM content, ‘pure’
GM and WM NAA concentrations were extrapolated from the end-
points of the linear ﬁt (Hetherington et al., 1996; Noworolski et al.,
1999).
Clinical measures
For all subjects, the Expanded Disability Status Scale (EDSS) (Kurtzke et
al., 1983), Multiple Sclerosis Functional Composite (MSFC) (Fischer
et al., 1999), Functional Assessment in MS (FAMS), and brain MR
scans (described above) were performed within 2 weeks of entry
into the study. CIS was deﬁned as the ﬁrst well-deﬁned neurological
event lasting 548h, involving the optic nerve, spinal cord, brainstem,
or cerebellum. In CIS patients, the presence of two or more hyperin-
tense lesions on a T2-weighted MRI sequence was also required for
enrollment into the study. The diagnosis of RRMS was made utilizing
the new International Panel criteria (McDonald et al., 2001; Polman
et al., 2005). SPMS was deﬁned by 6 months of worsening neurolo-
gical disability not explained by clinical relapse; deterioration was mea-
sured as either: (i) an increase of one or more points on the EDSS in
patients with scores56.0, or (ii) an increase of one-half point or more
for those with EDSS scores 56.0. PPMS was deﬁned both by (1)
progressive clinical worsening for 412 months from symptom onset
without any relapses, and (2) abnormal cerebrospinal ﬂuid (CSF) as
deﬁned by the presence of 52 oligoclonal bands or an elevated IgG
index. If acute relapses were superimposed on this steadily progressive
course, patients were considered to have PRMS.
MS functional composite protocol
Three formally trained research coordinators at the UCSF MS Center
administered the MSFC. Formal didactic descriptions and a standar-
dized protocol for administering the MSFC were utilized for all
patients. All examiners were blinded to MS subtype, DRB11501
status, and radiological outcomes. Instructions were provided in
English only. Testing order included: (i) 9-Hole Peg Test (9-HPT)
(two timed trials of the dominant hand performed in succession fol-
lowed by the assessment of the non-dominant hand), (ii) Paced
Auditory Serial Addition Test (PASAT-3) (single trial with 3-s inter-
stimulus intervals) and (iii) 25-Foot Timed Walk (25-FTW) (two-
timed trials). Attempts were made to ensure that the same MSFC
examiner performed all studies longitudinally for a given patient.
A single version of the PASAT (PASAT-3A), with score range from 0
to 60, was used. Directions were formally read to the patient and one
to three practice runs of 11 pre-selected numbers with 10 possible
responses provided prior to scoring. The test was aborted if patients
were unable to provide at least two non-consecutive correct answers
during the practice session. The test was also aborted, and number of
correct responses determined, if a request was made during the eva-
luation for the test to be terminated.
MSFC scores were derived by the methods previously described by
the National MS Society’s Clinical Assessment Task Force (Fischer
et al., 1999). Standardized scores (Z-scores) were calculated for the
9-HPT, PASAT-3, and 25-FTW representing the number of standard
deviation units of performance from the reference population (entire
MS cohort) mean. Z-Scores for the 9-HPT were calculated by aver-
aging the two trial times for each hand followed by conversion to an
averaged reciprocal time. The reciprocal mean performance time for
the reference population was subtracted from the individual patient’s
averaged reciprocal time then divided by the reference population
standard deviation. Z-scores for the 25-FTW were calculated by sub-
tracting the average time from the reference population from the
average of the two-timed 25-FTW trials then divided by the reference
population standard deviation. PASAT-3 performance was calculated
by determining the number of correct responses during a single trial
using a 3-s stimulus interval. Z-scores were calculated by determining
the difference between the patient’s performance and reference popu-
lation mean then divided by the reference population standard
deviation.
The MSFC score was derived by the following equation:
MSFC Score ¼½ðZ-score 1=9-HPTÞ þ ðZ-score 25-FTWÞ
þ ðZ-score PASAT-3Þ=3
Positive Z-scores represent the number of standard deviation units of
performance better than the reference population mean.
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FAMS
Self-Reported Questionnaires [FAMS (Version 4)] focusing on:
(i) emotional well-being; (ii) thinking and fatigue, and (iii) pain were
administered at baseline. Patients were advised to provide assessments
based on their experience over the past 7 days. Scores ranging from 0
(not at all) to 4 (very much) were assigned to the emotional well-being
(seven questions) and thinking and fatigue (nine questions) sections. A
Pain Intensity Numerical Rating Scale ranging from 0 (no pain) to 10
(worst possible pain) was used to assess pain intensity associated with
MS or MS treatments over the previous 12 months.
Statistical analysis
The frequency of DRB11501 was compared against gender, disease
subtype, age of disease onset, disease duration, presence or absence
of treatment, EDSS, T2-lesion volumes and gadolinium enhancement.
Box–Cox transformation was performed on T2-lesion volumes prior to
analysis for the treatment of non-normality (Box and Cox, 1964).
Kolmogorov-Smirnov test for normality was performed on the trans-
formed T2-lesion volumes and NAA concentrations. Analysis of
Covariance (ANCOVA) was used to assess for differences in the trans-
formed T2-lesion volumes between DRB11501 haplotypes. The dif-
ferences between the adjusted mean values [least-squares means
(LSMeans)] of the transformed T2-lesion volumes and NAA concen-
trations between haplotypes were compared using a Student’s T-test.
Multi-colinearity among the variables in the model was examined by
assessing the tolerance. Linear regression analysis was used to study
the association between DRB11501 carriers and NAA concentrations,
Box–Cox transformed T2-lesion volumes, and nBPV measurements
with relevant confounding variables incorporated in the model.
For the non-parametric analysis, the untransformed T2-lesion
volumes were divided into quartiles from Q1 to Q4; with Q1 repre-
senting lowest lesion volumes and Q4 containing the highest lesion
load. Logistic regression was used to assess the likelihood
of DRB11501 patients falling into the higher quartiles compared to
non-carriers. Data from Q1 was used as the reference category for
calculating the odds ratios (ORs) and degree of signiﬁcance (P-values).
Potential confounding variables were included in the model.
A Wilcoxon Two-sample test was performed comparing baseline
EDSS and FAMS scores in addition to 9-HPT, PASAT-3, and 25-FTW
Z-scores along with overall MSFC performance between DRB11501+
and DRB11501- MS patients. A generalized linear model (SAS v.9.1.3
GENMOD Procedure) was utilized, incorporating the maximum
likelihood estimation for regression coefﬁcients for important covari-
ates in the model (age, age of disease onset, disease duration, prior
exposure to immunotherapy, T2-lesion volumes, and baseline PASAT
Z-scores) and likelihood ratio test to examine the DRB11501 effect.
Multi-colinearity among the variables in the model was examined by
assessing tolerance.
All statistical analyses were performed using SAS v.9.1.3 (SAS
Institute Inc., North Carolina, USA). A P-value4 0.05 was considered
statistically signiﬁcant.
Results
A total of 511 patients were enrolled during the study period. Six
patients were excluded due to motion artifact on the MRI scan
(n=2) or lack of the appropriate MR dual-echo sequence per-
formed for lesion volume determination (n=4). Of the 505
cases available, the speciﬁc MS subtypes included: 88 CIS, 352
RRMS, 46 SPMS, 14 PPMS, three PRMS, and two patients with
an uncertain MS subtype. Table 1 summarizes the clinical data for
the entire cohort. The distribution of the clinical and demographic
data divided on the basis of DRB11501 haplotypes (either posi-
tive or negative) is shown in Table 2. The DRB11501+ group
had signiﬁcantly more women (74% versus 63%; P=0.009) and
a younger mean age at disease onset (32.4 years versus 34.3
years; P=0.025) compared to the DRB11501- group.
Spectroscopic metabolic data were acquired from 409 patients
(1501+: 185, 1501-: 224) of the 505 cases available (81%).
Table 3 summarizes the demographic and clinical data for these
patients. A signiﬁcantly lower concentration of NAA in the NAWM
was observed in the DRB11501+ group (P=0.025), with similar
mean concentrations of NAA identiﬁed in NAGM (P=0.221).
Linear regression analysis incorporating signiﬁcant covariates (e.g.
gender, age of disease onset, T2-lesion volume, and disease dura-
tion) on the effect of NAA concentration in NAWM continued to
demonstrate a statistically signiﬁcant concentration reduction in
the DRB11501+ group (P50.05).
Using ANCOVA, a greater value of the transformed
and adjusted T2-lesion volume, consistent with a higher burden
of disease, was found for the DRB11501+ group (see Methods
for details of this analysis). Back transformation of the adjusted
Table 1 Summary of the demographic and clinical data for the entire study cohort
N Mean Median Range
Age (Y) 503 42.1 42.0 17–65
Gender 505 F: 344(68%); M: 161(32%)
Age of disease onset (Y) 503 33.5 33.0 11–60
Disease duration (Y) 503 9.68 7.00 1.0–46.0
MS treatment exposure 505 YES: 348(69%); NO: 157(31%)
HLA-DRB1*1501 505 1501+: 232(46%); 1501-: 273(54%)
EDSS score 505 2.0 1.5 0.0–7.0
N-Acetyl-Aspartate – NAWM (mM) 409 9.96 9.89 6.86–14.47
MSFC score 487 0.051 0.208 4.920–1.186
T2-Lesion load (mm3) 503 7365.2 3082.3 0.0–87641.0
Normalized brain parenchymal volume (cm3) 504 1588.8 1600.9 1270.0–1821.9
Y= years; F = female; M=male; EDSS = expanded disability status scale; NAWM=normal appearing white matter; MSFC=multiple sclerosis functional composite.
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Table 3 Summary of the demographic and clinical data for patients undergoing 1HMR analysis
N Mean SD Median Range
Age (Y) 409 43.9 9.8 43.5 18.0–66.9
Gender 409 F: 274(67%); M: 135(33%)
Age of disease onset (Y) 409 33.6 9.4 33.0 11.0–59.0
Disease duration (Y) 409 10.0 9.0 7.1 0.0–46.0
MS treatment exposure 409 YES: 282(69%); NO: 127(31%)
HLA-DRB1*1501 409 1501+: 185(45%); 1501: 224(55%)
EDSS score 409 2.3 1.7 2.0 0.0–7.0
N-Acetyl-Aspartate – NAWM (mM) 409 9.96 1.28 9.89 6.86–14.47
1501+ (N=185) P=0.025 9.80 1.30 9.70 6.86–14.47
1501 (N=224) 10.10 1.30 10.10 7.12–13.67
T2-Lesion load (mm3) 409 7211.2 10972.9 3151.5 0.0–86610.3
Y= years; F = female; M=male; EDSS = expanded disability status scale; NAWM=normal appearing white matter.
Table 2 Summary of demographic and clinical data by HLA-DRB1*1501 haplotype
HLA-DRB1*1501 Mean SD Median P-value
Age (Y) 1501+ 41.4 9.9 41 0.116
1501 42.7 9.8 43
Gender 1501+ F: 171(74%); M: 60 (26%) 0.009
1501 F: 173(63%); M: 101(37%)
Age of disease onset (Y) 1501+ 32.4 8.8 32 0.025
1501 34.3 9.7 34
Disease duration (Y) 1501+ 9.99 8.5 7.0 0.170
1501 9.41 9.2 6.0
MS treatment exposure 1501+ YES: 163(71%); NO: 68(29%) 0.462
1501 YES: 185(68%); NO: 89(32%)
HLA-DRB1*1501 1501+ 232 (46%) 0.609
1501 273 (54%)
EDSS score 1501+ 1.9 1.6 1.5 0.201
1501 2.1 1.7 2.0
MSFC score 1501+ 0.082 0.631 0.197 0.434
1501 0.034 0.710 0.223
9-Hole peg testa 1501+ 0.003 0.958 0.116 0.738
1501 0.017 1.027 0.097
PASAT-3a 1501+ 0.110 1.070 0.128 0.004
1501 0.048 0.935 0.266
25-FTWa 1501+ 0.017 0.789 0.0001 0.119
1501 0.120 1.149 0.0329
T2-Lesion load (mm3) 1501+ 8109.8 13006 3337.1 0.031
1501 6786.2 10137 2828.5
Normalized brain 1501+ 1585.9 90.3 1589.6 0.023
parenchymal volume (cm3) 1501 1591.4 88.6 1607.6
Volume scaling factor 1501+ 1.33 0.11 1.33 0.600
1501 1.34 0.12 1.33
a Z Score. Y = years; F = female; M=male; EDSS= expanded disability status scale; MSFC=multiple sclerosis functional composite; PASAT=paced auditory serial addition
test; 25-FTW=25-Foot timed walk.
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means showed a 1,127mm3 greater lesion volume in the
DRB11501 group compared to all other DRB1 alleles (P=0.031).
Non-parametric statistical methods were used to compare the
quartiles for untransformed T2-lesion volumes and to conﬁrm the
results obtained from the parametric statistical analysis. Gender
(P=0.652) and HLA-DRB11501 status (P=0.066) were not asso-
ciated with T2-lesion volume (Table 4). By contrast, age
(P=0.030), age at disease onset (P50.0001), disease duration
(P50.0001), previous exposure to immunotherapy (P50.0001)
and EDSS (P50.0001) were associated with greater T2-lesion
volumes. DRB11501+ subjects classiﬁed with CIS, RRMS, and
SPMS were 1.90 times (P=0.015) more likely to have higher
T2-lesion volumes with values falling into Q2 versus Q1 and
1.69 times more likely to fall into Q3 versus Q1 (P=0.049)
when age of disease onset, duration of disease, and DRB11501
status were included as predictors. Signiﬁcant differences were not
observed in the ORs when comparing Q4 versus Q1 (P=0.314).
Logistic regression did not reveal substantial differences in the
ORs or statistical signiﬁcance with the addition of potentially
confounding covariates (Table 5). Inclusion of the PPMS and
PRMS subtypes revealed similar ORs and degrees of signiﬁcance
between quartiles (data not shown).
Linear regression analysis, incorporating signiﬁcant covariates
(i.e. age of disease onset, gender, duration of disease, EDSS,
and exposure to treatment), revealed a signiﬁcant reduction in
nBPV for the DRB11501+ group with a least squares mean dif-
ference of 14 cm3 (P=0.023) observed, representing a 0.9%
reduction in the total brain volume between DRB11501 carriers
and non-carriers. No signiﬁcant difference was observed in the
normalized scalling factors for both groups.
Analysis of the impact of DRB11501 on cognitive function
revealed a statistically signiﬁcant difference in PASAT-3 perfor-
mance between haplotypic groups (P=0.004), a result that
remained signiﬁcant after a sensitivity analysis for potential con-
founders (P50.005). Patient age, disease duration, EDSS, FAMS,
and MSFC scores, along with exposure to immunotherapy, the
type of such therapy, and the presence of gadolinium enhancing
lesions were similar between groups.
Table 4 Summary of the demographic and clinical data by T2-lesion load quartiles
Q1 Q2 Q3 Q4
T2-Lesion load (mm3) N=126 N=126 N=126 N=125
Mean=335.07 Mean= 1889.45 Mean=5336.18 Mean= 22016.27
SD=254.38 SD=631.06 SD=1527.66 SD=15222.37
Median =297.62 Median =1882.95 Median =5121.50 Median =16386.55
Range: 0–887.92 Range: 915.60–3082.32 Range: 3119.24–8738.09 Range: 8864.65–87641.24
Age (Y) N=125 N=125 N=126 N=125
P=0.030 Mean=39.9 Mean= 41.9 Mean=42.8 Mean= 43.7
SD=9.1 SD=9.6 SD=9.7 SD=10.8
Median =40.0 Median =42.0 Median =41.5 Median =43.0
Range: 17–65 Range: 18–64 Range: 23–63 Range: 19–65
Gender F: 87 (25.5%) F: 87 (25.5%) F: 88 (25.8%) F: 79 (23.2%)
P=0.652 M: 39 (24.1%) M: 39 (24.0%) M: 38 (23.5%) M: 46 (28.4%)
Age at disease onset (Y) N=125 N=125 N=126 N=125
P50.0001 Mean=34.5 Mean= 35.2 Mean=33.6 Mean= 30.3
SD=8.6 SD=8.6 SD=9.7 SD=9.4
Median =35.0 Median =35.0 Median =32.0 Median =29.7
Range: 13–55 Range: 17–58 Range: 17–60 Range: 11–58
Disease duration (Y) N=125 N=125 N=126 N=125
P50.0001 Mean=6.5 Mean= 7.7 Mean=10.2 Mean= 14.4
SD=6.5 SD=7.1 SD=8.6 SD=10.7
Median =4.0 Median =5.0 Median =7.0 Median =12.0
Range: 1–35 Range: 1–38 Range: 1–37 Range: 1–46
MS treatment exposure NO: 59 (47.2%) NO: 36 (28.8%) NO: 34 (27.0%) NO: 27 (21.6%)
P50.0001 YES: 66 (52.8%) YES: 89 (71.2%) YES: 92 (73.0%) YES: 98 (78.4%)
HLA-DRB1*1501 1501+: 45 (19.7%) 1501+: 64 (28.0%) 1501+: 62 (27.2%) 1501+: 57 (25.0%)
P=0.066 1501: 80 (29.4%) 1501: 61 (22.4%) 1501: 62 (22.8%) 1501: 69 (25.4%)
EDSS score N=125 N=125 N=126 N=125
P50.0001 Mean=1.58 Mean= 1.77 Mean=1.97 Mean= 2.72
SD=1.50 SD=1.46 SD=1.43 SD=1.93
Median =1.5 Median =1.5 Median =1.5 Median =2.0
Range: 0–7 Range: 0–6 Range: 0–6 Range: 0–7
Y= years; F = female; M=male; EDSS = expanded disability status scale.
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Discussion
An effect of the HLA-DRB11501 gene on four domains
of disease severity in MS was identiﬁed: (i) a reduction in NAA
concentration within NAWM by MR spectroscopy suggesting
alterations in neuronal integrity not discernable through conven-
tional techniques, (ii) a higher adjusted mean T2-lesion volume
utilizing conventional MR measures, (iii) reduced normalized
brain volume utilizing high-resolution images, and (iv) impairments
in cognitive function as measured by PASAT-3 performance.
Taken together, these data, derived from a large and prospectively
ascertained population, indicate that DRB11501 increases disease
severity in MS by facilitating the development of more T2-foci,
which has the potential of transecting axons, leading to wide-
spread axonal compromise (reduction of NAA in NAWM) and
subsequent degeneration with resultant brain atrophy and asso-
ciated injury suggested by the presence of cognitive impairment
(decline in PASAT-3 performance).
Disease-modifying therapies for MS, used by many patients
in the cohort, were unlikely to have inﬂuenced the outcomes
reported here. The proportion of patients treated with interferon
(IFN), glatiramer acetate (GA), or immune suppression was similar
between the DRB11501+ and DRB11501- groups, as was the
total duration of treatment. One earlier unconﬁrmed study with
limited power suggested the presence of an interaction between
DRB11501 and a treatment response to GA (Fusco et al., 2001).
However, this effect, if present, would have biased results in the
opposite direction to those observed here (i.e. GA treated
DRB11501+ patients would have been expected to accumulate
fewer focal MS lesions). We previously reported, in a different
population of MS patients, that responses to IFN are not inﬂu-
enced by DR status (Villoslada et al., 2002). Interestingly, the
inﬂuence of DRB11501 on T2-lesion volume appeared to
decrease as the total burden of disease increased. With increasing
T2-lesion volume there is less remaining normal WM at risk for
demyelination, which could slow the accumulation of new focal
lesions and blunt any inter-group differences.
The metabolite N-acetyl-aspartic acid is principally viewed as a
marker of neural integrity, because of its high concentration in
neurons, dendrites, axons, and synapses in the CNS (Birken and
Oldendorf, 1989; Simmons et al., 1991). NAA concentrations are
known to be reduced in chronic MS lesions (van Walderveen
et al., 1999), a ﬁnding interpreted as neuronal or axonal loss,
although questions remain unanswered with regard to the
dynamic nature of NAA changes and their reversibility or irrever-
sibility (Oh et al., 2004). Previous studies of NAA in NAWM
employed single-voxel MRS techniques that have lower spatial
resolution than the 2D multi-voxel modality used in this study,
precluding ﬁrm associations from being identiﬁed. In an earlier
study of NAWM in the corpus callosum of MS patients, we
reported reduced NAA values (Oh et al., 2004). In RRMS and
SPMS, these MR outcomes were strongly inﬂuenced by the pre-
sence of distant pericallosal MS lesions, consistent with a second-
ary degenerative process (i.e. Wallerian degeneration) occurring in
normal appearing brain regions. The difference observed here
in NAA concentrations suggest that a reduction in axonal density
or integrity is associated with the presence of DRB11501.
Longitudinal studies are in progress, and these should better
deﬁne the evolution of spectroscopic metabolite concentrations
in normal appearing brain regions, especially as patients transition
from the relapsing to the progressive stage of MS.
Cognitive impairment in MS is a common cause of clinical dis-
ability in MS, and a symptom that exhibits discordant features
with the degree of motor impairment (Piras et al., 2003). That
DRB11501 patients have a higher T2 burden of disease and
reduced brain parenchymal volume suggested the possibility of a
difference in cognitive impairment in DRB11501 patients com-
pared to other DRB1 alleles. T2-lesion volume and brain atrophy
Table 5 Logistic regression analysis and effect of potential confounders on T2-lesion load volume
Logistic regression equation R2 Q2/Q1
Odds ratio
95% CI
Q3/Q1
Odds ratio
95% CI
Q4/Q1
Odds ratio
95% CI
RR/SP/CIS (N=483) T2LL=AODO+DD+DRB1*1501 0.15 1.90 1.69 1.32
P=0.015 P=0.049 P=0.314
1.13–3.20 1.00–2.86 0.77–2.29
RR/SP/CIS (N=483) T2LL=AODO+DD+EDSS +DRB1*1501 0.18 1.92 1.74 1.38
P=0.014 P=0.039 P=0.258
1.14–3.23 1.03–2.94 0.79–2.40
RR/SP/CIS (N=482) T2LL=AODO+TX+DD+DRB1*1501 0.19 1.97 1.76 1.39
P=0.012 P=0.038 P=0.245
1.16–3.33 1.03–3.00 0.80–2.43
RR/SP/CIS (N=482) T2LL=AODO+TX+DD+EDSS +DRB1*1501 0.21 1.97 1.79 1.44
P=0.012 P=0.032 P=0.210
1.16–3.35 1.05–3.06 0.82–2.52
RR= relapsing-remitting MS; SP= secondary-progressive MS; CIS = clinically isolated syndrome; T2LL= T2-lesion load; AODO=age of disease onset; DD=disease
duration; TX= exposure to MS treatment.
Signiﬁcance of bold values is P40.05.
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were previously correlated with the evolution of cognitive decline
in MS (Rao et al., 1989, 1991; Piras et al., 2003; Houtchens et al.,
2007). The presence of T2-foci is directly associated with irrever-
sible axonal transection and compromise (Trapp et al., 1998);
thereby providing an explanation for previous studies demonstrat-
ing the association between burden of disease and cognitive integ-
rity. Compromises in cognitive function, signiﬁed by PASAT-3
performance, may also be related to subsequent secondary degen-
eration, as observed in our dataset with signiﬁcant changes
noted between DRB11501 groups and brain volumes normalized
for intracranial skull size. Investigations correlating both semi and
fully automated whole brain volumetric techniques to cognitive
performance in MS are nascent and deﬁnitive data controlling
for important covariates are deﬁcient. More recently, NAA con-
centration and executive function in healthy individuals were also
correlated, suggesting alterations in brain integrity not appreciated
with conventional techniques (Charlton et al., 2007). Efforts were
made in this study to ensure that fatigue and mood disorders
were not potential contributors to a decline in PASAT-3 perfor-
mance. The lack of statistical differences in self-reported FAMS
scores suggests that these were not signiﬁcant contributing fac-
tors. It is likely that the correlations between NAA, T2-lesion
volume, nBPV and PASAT-3 observed here provide overlapping
evidence for an association between HLA-DRB11501 and MS
severity (Fig. 1).
The gene products of DRB11501 in white populations, and the
closely related DRB11503 in blacks, share in common a structu-
rally related hydrophobic peptide-binding motif facilitating tight
binding to aromatic amino acids that includes the critical aa92
(Phe) residue of the 89–96 region of myelin basic protein
(MBP). This peptide sequence is known to be immunodominant
in DRB11501 individuals, resulting in efﬁcient presentation of
MBP 89–96, or a related cross-reactive (possibly viral) peptide,
to T cells (Ota et al., 1990; Wucherpfennig et al., 1994, 1995),
speciﬁc activation of T cells in the circulation of DRB11501 indi-
viduals with MS (Allegretta et al., 1990; Scholz et al., 1998), and
the presence of 89–96 MBP reactive T cells in MS plaques
(Oksenberg et al., 1993). By analogy to animal models of T cell
mediated autoimmune demyelination (Zamvil et al., 1985), early
in the disease course focal lesions may result from a relatively
limited number of pathogenic T cell speciﬁcities. Over time, epi-
tope spreading may occur, increasing the number of autoantigen
targets recognized by pathogenic T cells and the diversity of HLA
restricting elements mediating the disease. We would speculate
that, in DRB11501+ individuals with MS, high numbers of
MBP-reactive T cells stochastically favour the development of
more focal lesions early in the disease course, and also greater
concentration of encephalitogenic T cells in lesions favouring sec-
ondary axonal degeneration measured as loss of NAA in NAWM.
Continued intra- and inter-molecular epitope spreading, as well as
the development of pathogenic T cell responses not restricted to
DRB11501, could modulate this effect of DRB11501 over time.
This biologically plausible mechanism, in addition to the lack of
neurodegeneration observed without inﬂammation in animal
models (Lorentzen et al., 1995; Zhou et al., 2006), supports our
rationale of a mechanistic cascade of disease severity.
In summary, these results demonstrate a robust association
between the DRB11501 haplotype and MS disease severity. An
association between DRB11501 and disease severity, as mea-
sured by spectroscopic metabolic differences, with a reduction in
the concentration of NAA in NAWM was observed; the result of
an increased burden of disease observed on conventional anatomic
imaging as well as disease in NAWM not yet discernable utilizing
conventional MRI techniques. These imaging ﬁndings, along with
alterations in nBPV between groups, are likely responsible for the
alterations in cognitive integrity observed. Longitudinal studies—
combining imaging, genetic, and clinical variables, in addition to
other biomarkers are currently underway to test and extend these
cross-sectional ﬁndings. These technologies offer a remarkable
opportunity to investigate heterogeneity in MS. In another exam-
ple, we have recently reported that expression proﬁling of CD4
cells can robustly predict the future behaviour of CIS patients for
period of 1 year (Corvol et al., 2008). The overall goal of a deep
phenotypic approach to MS is to develop an array of meaningful
biomarkers to monitor the course of the disease, predict its future
behaviour, determine when treatment is necessary, and perhaps
also select from among available therapies. Longitudinal studies,
combining imaging, genetic, and clinical outcomes, in addition to
other biomarkers, are currently underway to afﬁrm and extend
these novel data. Similar studies and results from independent
datasets would also provide additional conﬁrmation. Overall,
these efforts are likely to substantially clarify the underlying biol-
ogy of MS.
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